RVPH enters its most consequential week of the year not because of earnings — though those came too — but because the stock is being delisted from Nasdaq, with shares moving to the OTCQB market on May 14.
The delisting overshadows everything else. Confirmed today, the transition to OTCQB marks a structural shift for the company: reduced visibility, a smaller eligible investor base, and typically higher friction for institutional participants. Shares closed at $0.7954 on May 12, down 2.6% on the week. Q1 earnings landed after the bell on May 13, with EPS of -$0.46 beating the -$0.62 consensus estimate — a meaningful beat, but one arriving on the eve of the exchange migration rather than from a position of strength.
Short interest had been building sharply through late April, peaking near 2.6 million shares around April 23. Then came a swift reversal. By May 12, short interest had collapsed 39% in a single week to 1.28% of the free float — roughly 1.47 million shares. The move looks like deliberate cover-off ahead of the delisting: borrow conditions remain elevated, with the cost to borrow running near 8.2% and availability a very tight 14.8% of short interest. With fewer than 15 shares available for every 100 already borrowed, the lending market remains constrained. The ORTEX short score has also eased — falling from 77.1 on April 30 to 71.6 by May 12 — but it remains firmly elevated, ranking in the bottom 9th percentile of the universe for short-score pressure.
The Street picture is fractured. Maxim Group downgraded to Hold on April 8, pulling the consensus to a single hold rating. That move followed a Roth Capital target cut to $1.00 from $1.50 on March 31. Alliance Global Partners is an outlier: the firm actually raised its target to $30 from $16 on March 30 — a number that is difficult to reconcile with RVPH trading near $0.80 and should be treated with significant caution. More credible coverage from HC Wainwright and D. Boral Capital has been ratcheting targets lower for over a year, from highs of $11 and $8 respectively down to $4 and $2 today. The bull case rests entirely on brilaroxazine, the company's lead CNS asset, and whether late-stage data can unlock a clear regulatory pathway. The bear case centres on dilution risk — the company will almost certainly need to raise capital, and the delisting makes that task harder.
Institutional ownership tells an interesting side story. Millennium Management reported holding 793,952 shares (6.2% of the company) as of late March, having added 680,779 shares in the quarter. UBS Asset Management filed a 13G on May 7, disclosing 746,095 shares (5.8%) — nearly all of it a new position. Heights Capital also built a fresh stake of 666,667 shares. Whether these positions were accumulated as part of a financing arrangement or as outright market purchases is not clear from the filings, but the concentration of recent new institutional activity is notable for a $10 million market-cap name heading to OTC markets.
Looking at recent earnings reactions gives little comfort. The November 2025 release sent the stock up 10% on the day before giving back most of the gain over five sessions. A separate November 2025 event pushed shares down 13% in a day. The April 15 print produced a modest 2% daily gain and a 8% five-day move. The range of outcomes is wide, and tonight's Q1 beat may struggle to compete with the delisting news as the dominant driver tomorrow.
The stock to watch is no longer the Nasdaq-listed RVPH — it is whatever begins trading on OTCQB on May 14, where liquidity, analyst coverage, and institutional participation are all likely to be materially different.
See the live data behind this article on ORTEX.
Open RVPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
